Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473603 | 1.00 | ALDH1A1 (0.66) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL417140 | 0.89 | ALDH1A1 (0.63) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL27579381 | 0.86 | LTA4H (0.59) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL12578080 | 0.85 | POLB (0.60) | ALDH1A1POLBL3MBTL1MAPT | |
| SCHEMBL17521455 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBL3MBTL1KIF11TLR8 | |
| SCHEMBL924185 | 0.84 | ADAMTS5 (0.55) | ALDH1A1POLBL3MBTL1KIF11NR3C1 | |
| SCHEMBL23244709 | 0.84 | L3MBTL1 (0.51) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL9105483 | 0.84 | L3MBTL1 (0.51) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL13970668 | 0.83 | POLB (0.52) | ALDH1A1POLBL3MBTL1LTA4HKIF11 | |
| SCHEMBL184377 | 0.83 | PARP10 (0.50) | ALDH1A1POLBL3MBTL1LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380817-B | Benzimidazolo 2-amino-1, 3, 4-thiadiazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-114380817-A | Benzimidazole 2-amino-1, 3, 4-thiadiazole compound and preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| EP-1406861-A1 | SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT | Pfizer Products Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6720330-B2 | INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030208081-A1 | Substituted aromatic ethers as inhibitors of glycine transport | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| US-6566550-B2 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | PFIZER INC | 2003-05-20 | — | — | US | disclosed |
| US-20030013887-A1 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | PFIZER INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2003000646-A1 | SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | HAY BRUCE A (US) | 2002-07-11 | — | — | US | disclosed |
| US-5403934-A | Heterocyclic compounds | BURROUGHS WELLCOME CO. (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1991013873-A1 | HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-09-19 | — | — | WO | disclosed |
| EP-0447164-A1 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013887-A1 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | SLC1A2, SLC1A1, SLC1A3 | ALDH1A1 1330/4885POLB 4283/4885L3MBTL1 2443/4885 |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | ALDH1A1 3675/4885POLB 1644/4885L3MBTL1 3983/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | ALDH1A1 2042/4885POLB 1385/4885L3MBTL1 3358/4885 |
| US-20030208081-A1 | Substituted aromatic ethers as inhibitors of glycine transport | SLC1A2, SLC1A1, SLC6A1 | ALDH1A1 2156/4885POLB 4491/4885L3MBTL1 2919/4885 |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | SSTR2, GHSR, SSTR1 | ALDH1A1 3752/4885POLB 4439/4885L3MBTL1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.